TRT Cardiovascular Risk — Guidelines vs. Evidence
How major society guidance on testosterone therapy cardiovascular safety compares to the landmark trial evidence RAGMD has indexed.
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
RAGMD evidence position
Testosterone replacement therapy does not significantly increase major adverse cardiovascular events in hypogonadal men with elevated cardiovascular risk.
Guideline vs. evidence
| Guideline | Society position | RAGMD evidence |
|---|---|---|
| Endocrine Society (2018) | Recommends against TRT in men with uncontrolled heart failure or recent MI/stroke; emphasizes individualized risk-benefit assessment. | TRAVERSE (N=5,246) found noninferior MACE rates vs. placebo in hypogonadal men with CVD or high risk — the largest RCT directly addresses this question.Open evidence analysis → |
| AHA / ACC (general CVD prevention) | Focuses on lifestyle and established CV risk factors; does not provide specific TRT cardiovascular outcome guidance. | RAGMD synthesizes TRAVERSE and observational cohorts (Vigen, Baillargeon) — observational harm signals conflict with RCT data due to confounding.Open evidence analysis → |
| FDA labeling | Requires testosterone products to carry cardiovascular risk language based on historical observational signals. | Post-TRAVERSE, the evidence base is anchored on RCT noninferiority; labeling reflects precautionary stance rather than trial-confirmed harm.Open evidence analysis → |
Key studies
- TRAVERSE primary MACE outcome · PMID 37326322
- Vigen observational cohort (conflicting) · PMID 24141714